324 related articles for article (PubMed ID: 25269954)
1. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.
Stacchiotti S; Tortoreto M; Baldi GG; Grignani G; Toss A; Badalamenti G; Cominetti D; Morosi C; Dei Tos AP; Festinese F; Fumagalli E; Provenzano S; Gronchi A; Pennacchioli E; Negri T; Dagrada GP; Spagnuolo RD; Pilotti S; Casali PG; Zaffaroni N
Eur J Cancer; 2014 Nov; 50(17):3021-8. PubMed ID: 25269954
[TBL] [Abstract][Full Text] [Related]
2. Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics.
Stacchiotti S; Tortoreto M; Bozzi F; Tamborini E; Morosi C; Messina A; Libertini M; Palassini E; Cominetti D; Negri T; Gronchi A; Pilotti S; Zaffaroni N; Casali PG
Clin Cancer Res; 2013 Sep; 19(18):5192-201. PubMed ID: 23888069
[TBL] [Abstract][Full Text] [Related]
3. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
Martin-Broto J; Stacchiotti S; Lopez-Pousa A; Redondo A; Bernabeu D; de Alava E; Casali PG; Italiano A; Gutierrez A; Moura DS; Peña-Chilet M; Diaz-Martin J; Biscuola M; Taron M; Collini P; Ranchere-Vince D; Garcia Del Muro X; Grignani G; Dumont S; Martinez-Trufero J; Palmerini E; Hindi N; Sebio A; Dopazo J; Dei Tos AP; LeCesne A; Blay JY; Cruz J
Lancet Oncol; 2019 Jan; 20(1):134-144. PubMed ID: 30578023
[TBL] [Abstract][Full Text] [Related]
4. Response to chemotherapy of solitary fibrous tumour: a retrospective study.
Stacchiotti S; Libertini M; Negri T; Palassini E; Gronchi A; Fatigoni S; Poletti P; Vincenzi B; Dei Tos AP; Mariani L; Pilotti S; Casali PG
Eur J Cancer; 2013 Jul; 49(10):2376-83. PubMed ID: 23566418
[TBL] [Abstract][Full Text] [Related]
5. Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study.
Stacchiotti S; Simeone N; Lo Vullo S; Morosi C; Greco FG; Gronchi A; Barisella M; Collini P; Zaffaroni N; Dagrada GP; Frezza AM; Mariani L; Casali PG
Eur J Cancer; 2019 Jan; 106():225-233. PubMed ID: 30528807
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib malate in solitary fibrous tumor (SFT).
Stacchiotti S; Negri T; Libertini M; Palassini E; Marrari A; De Troia B; Gronchi A; Dei Tos AP; Morosi C; Messina A; Pilotti S; Casali PG
Ann Oncol; 2012 Dec; 23(12):3171-3179. PubMed ID: 22711763
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib in advanced solitary fibrous tumour: Results from an exploratory phase II clinical study.
Stacchiotti S; Baldi GG; Frezza AM; Morosi C; Greco FG; Collini P; Barisella M; Dagrada GP; Zaffaroni N; Pasquali S; Gronchi A; Huang P; Ingrosso M; Tinè G; Miceli R; Casali PG
Eur J Cancer; 2023 Dec; 195():113391. PubMed ID: 37918286
[TBL] [Abstract][Full Text] [Related]
8. Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental Endometriosis in Rats.
Yildiz C; Kacan T; Akkar OB; Karakus S; Kacan SB; Ozer H; Cetin A
Reprod Sci; 2015 Nov; 22(11):1445-51. PubMed ID: 25963915
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial.
Martin-Broto J; Cruz J; Penel N; Le Cesne A; Hindi N; Luna P; Moura DS; Bernabeu D; de Alava E; Lopez-Guerrero JA; Dopazo J; Peña-Chilet M; Gutierrez A; Collini P; Karanian M; Redondo A; Lopez-Pousa A; Grignani G; Diaz-Martin J; Marcilla D; Fernandez-Serra A; Gonzalez-Aguilera C; Casali PG; Blay JY; Stacchiotti S
Lancet Oncol; 2020 Mar; 21(3):456-466. PubMed ID: 32066540
[TBL] [Abstract][Full Text] [Related]
10. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
[TBL] [Abstract][Full Text] [Related]
11. Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.
Stacchiotti S; Saponara M; Frapolli R; Tortoreto M; Cominetti D; Provenzano S; Negri T; Dagrada GP; Gronchi A; Colombo C; Vincenzi B; Badalamenti G; Zuco V; Renne SL; Collini P; Morosi C; Dei Tos AP; Bello E; Pilotti S; Casali PG; D'Incalci M; Zaffaroni N
Eur J Cancer; 2017 May; 76():84-92. PubMed ID: 28284173
[TBL] [Abstract][Full Text] [Related]
12. [Multikinase inhibitors as a new approach in neovascular age-related macular degeneration (AMD) treatment: in vitro safety evaluations of axitinib, pazopanib and sorafenib for intraocular use].
Thiele S; Liegl RG; König S; Siedlecki J; Langer J; Eibl K; Haritoglou C; Kampik A; Kernt M
Klin Monbl Augenheilkd; 2013 Mar; 230(3):247-54. PubMed ID: 23508753
[TBL] [Abstract][Full Text] [Related]
13. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.
Kumar R; Crouthamel MC; Rominger DH; Gontarek RR; Tummino PJ; Levin RA; King AG
Br J Cancer; 2009 Nov; 101(10):1717-23. PubMed ID: 19844230
[TBL] [Abstract][Full Text] [Related]
14. Signaling inhibitors in metastatic renal cell carcinoma.
Escudier B
Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response.
Stacchiotti S; Negri T; Palassini E; Conca E; Gronchi A; Morosi C; Messina A; Pastorino U; Pierotti MA; Casali PG; Pilotti S
Mol Cancer Ther; 2010 May; 9(5):1286-97. PubMed ID: 20457621
[TBL] [Abstract][Full Text] [Related]
16. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
[TBL] [Abstract][Full Text] [Related]
17. Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Leung HW; Chan AL
Clin Ther; 2011 Jun; 33(6):708-16. PubMed ID: 21704235
[TBL] [Abstract][Full Text] [Related]
18. Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis.
Katz D; Azraq Y; Eleyan F; Gill S; Peretz T; Merimsky O
BMC Cancer; 2016 Aug; 16():616. PubMed ID: 27501793
[TBL] [Abstract][Full Text] [Related]
19. Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
Fiorio Pla A; Brossa A; Bernardini M; Genova T; Grolez G; Villers A; Leroy X; Prevarskaya N; Gkika D; Bussolati B
BMC Cancer; 2014 Dec; 14():939. PubMed ID: 25494980
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; Santini D; Cascinu S
J Urol; 2015 Jan; 193(1):41-7. PubMed ID: 25046616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
